摘要
目的探讨胱抑素C(CysC)临床检测在肾脏疾病中的应用。方法选择2018年1月—2020年12月枣庄矿业集团枣庄医院收治的150例肾脏疾病患者作为肾脏疾病组,并根据疾病类型分为肾功能不全代偿组、肾功能不全失代偿组、肾功能衰竭组,每组各50例;另外选择同期50名健康体检者作为正常对照组。采用免疫比浊法检测CysC,采用酶偶联率法检测尿素,采用比色法检测血肌酐(SCr),比较并分析各组上述指标水平以及阳性检出率的差异。结果肾脏疾病组的CysC、尿素、SCr水平〔CysC(mg/L):5.05±0.46比1.03±0.17,尿素(mmol/L):12.62±1.78比5.37±1.22,SCr(μmol/L):165.44±25.78比80.45±10.36〕和阳性检出率〔CysC:88.00%(132/150)比0.00%(0/50),尿素:60.67%(91/150)比0.00%(0/50),SCr:67.33%(101/150)比2.00%(1/50)〕均明显高于正常对照组(均P<0.05)。肾功能衰竭组的CysC、尿素、SCr水平〔CysC(mg/L):5.22±0.51比4.56±0.82、2.65±0.32,尿素(mmol/L):22.75±4.13比10.38±1.52、5.78±1.25,SCr(μmol/L):750.60±35.58比174.51±19.67、92.45±20.36〕和阳性检出率〔CysC:100.00%(50/50)比86.00%(43/50)、78.00%(39/50),尿素:92.00%(46/50)比78.00%(39/50)、12.00%(6/50),SCr:98.00%(49/50)比82.00%(41/50)、22.00%(11/50)〕均明显高于肾功能不全失代偿组和肾功能不全代偿组(均P<0.05),且肾功能不全失代偿组的CysC、尿素、SCr水平〔CysC(mg/L):4.56±0.82比2.65±0.32,尿素(mmol/L):10.38±1.52比5.78±1.25,SCr(μmol/L):174.51±19.67比92.45±20.36〕及阳性检出率〔CysC:86.00%(43/50)比78.00%(39/50),尿素:78.00%(39/50)比12.00%(6/50),SCr:82.00%(41/50)比22.00%(11/50)〕均明显高于肾功能不全代偿组(均P<0.05)。结论CysC在肾脏疾病诊断中价值较高,可为该疾病的临床诊断和治疗方案制定提供参考。
Objective To investigate the effect of clinical detection of cystatin C(CysC)in kidney disease.Methods 150 patients with renal diseases admitted in Zaozhuang Hospital of Zaozhuang Mining Group from January 2018 to December 2020 were selected as kidney disease group,according to type of disease,the patients were divided into renal insufficiency compensation group,renal insufficiency decompensation group and renal failure group,with50 cases in each group;50 healthy subjects were selected as control group.Cys C was detected by immunoturbidimetric assay,urea was detected by enzyme coupling rate method,and serum creatinine(SCr)was detected by colorimetric method.Results In kidney disease group,Cys C,urea and SCr levels[Cys C(mg/L):5.05±0.46 vs.1.03±0.17,urea(mmol/L):12.62±1.78 vs.5.37±1.22,SCr(μmol/L):165.44±25.78 vs.80.45±10.36]and positive rates[Cys C:88.00%(132/150)vs.0.00%(0/50),urea:60.67%(91/150)vs.0.00%(0/50),SCr:67.33%(101/150)vs.2.00%(1/50)]were higher than those in control group(all P<0.05).In kidney disease group,Cys C,urea and SCr levels in renal failure group[Cys C(mg/L):5.22±0.51 vs.4.56±0.82,2.65±0.32,urea(mmol/L):22.75±4.13 vs.10.38±1.52,5.78±1.25,SCr(μmol/L):750.60±35.58 vs.174.51±19.67,92.45±20.36]and positive rates[Cys C:100.00%(50/50)vs.86.00%(43/50),78.00%(39/50),urea:92.00%(46/50)vs.78.00%(39/50),12.00%(6/50),SCr:98.00%(49/50)vs.82.00%(41/50),22.00%(11/50)]were higher than those in renal insufficiency decompensation group and renal insufficiency compensation group(all P<0.05).The Cys C,urea and SCr levels[Cys C(mg/L):4.56±0.82 vs.2.65±0.32,urea(mmol/L):10.38±1.52 vs.5.78±1.25,SCr(μmol/L):174.51±19.67 vs.92.45±20.36]and positive rates[Cys C:86.00%(43/50)vs.78.00%(39/50),urea:78.00%(39/50)vs.12.00%(6/50),SCr:82.00%(41/50)vs.22.00%(11/50)]in renal insufficiency decompensation group were significantly higher than those in renal insufficiency compensation group(all P<0.05).Conclusion Cys C has high value in the diagnosis of kidney disease,which can provide reference for the differential diagnosis and treatment of kidney disease.
作者
樊新晶
Fan Xinjing(Clinical Laboratory,Zaozhuang Hospital of Zaozhuang Mining Group,Zaozhuang 277100,Shandong,China)
出处
《实用检验医师杂志》
2021年第1期19-21,共3页
Chinese Journal of Clinical Pathologist
关键词
胱抑素C
肾功能衰竭
肾功能不全失代偿
肾功能不全代偿
Cystatin C
Renal failure
Renal insufficiency decompensation
Renal insufficiency compensation
